dermatology

R&D

Partner Content

Champion Innovation at the 7th Dermatology Drug Development ...

Following 6 FDA approvals of JAK inhibitors and the breakthroughs of the first approved therapies in Prurigo Nodularis, Alopecia Areata and a gene therapy for Dystrophic Epidermolysis Bullo

News

Leo builds dermatology pipeline with Timber deal

Denmark's Leo Pharma has agreed to buy US medical dermatology company Timber Pharmaceuticals in a move that will expand its pipeline of therapies for rare skin diseases.

R&D

Strong solutions for increasing dermatology research diversi...

As a woman of colour, I am very careful about the skin care products I use. I must be.

News

Nektar says Lilly got it wrong on eczema drug rezpeg

Nektar Therapeutics says that Eli Lilly made a big mistake when it reported data on a pair of phase 1b trials of its rezpegaldesleukin drug in atopic dermatitis and psoria

News

Almirall eyes pipeline expansion with €200m funding

Spanish pharma Almirall has closed a €200 million share capital raise that will be used in part to close pipeline-boosting activities – including bolt-on acquisitions and

News

Cosentyx nod ends 10-year drought in new biologics for HS

Novartis’ IL-17 inhibitor Cosentyx has become the first new biological therapy for the painful skin condition hidradenitis suppurativa (HS) in nearly a decade, following i

Champion Innovation at the 7th Dermatology Drug Development ...

Leo builds dermatology pipeline with Timber deal

Strong solutions for increasing dermatology research diversi...

Nektar says Lilly got it wrong on eczema drug rezpeg

Almirall eyes pipeline expansion with €200m funding

Cosentyx nod ends 10-year drought in new biologics for HS

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

dermatology

Editor's Picks